

DISCLOSURE UNDER REGULATION 14 OF SEBI (SHARE BASED EMPLOYEE BENEFITS), REGULATIONS, 2014

Sr. No	Particulars	Artemis Medicare Management Stock Option Plan – 2021 (“the Plan”)
A.	Any material change in the Plan and whether the Plan is in compliance with the regulation	The Shareholder approved the Plan vide Postal Ballot on 14 th March, 2021 and thereafter no material changes was incorporated in the Plan. Further, the Plan is in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014.
B.	Details related to the Plan :	
(i)	A description of the Plan that existed at any time during the year, including the general terms and conditions of the Plan, including -	
	(a) Date of shareholders’ approval	The shareholders approved the Plan and grants to Eligible employees under regulation 6(3)(d) of the SEBI (Share Based Employee Benefits), Regulations, 2014 through Postal Ballot resolution dated 14 th March, 2021.
	(b) Total number of stock options approved under the Plan	The maximum number of Options approved pursuant to the Plan is 6,96,700 (Six Lac Ninety-Six Thousand Seven Hundred) which shall be convertible into equal number of Equity Shares of the Company.
	(c) Vesting requirements	As per the Plan, vesting period shall commence after minimum One (1) year from the grant date and it may extend upto maximum of Four (4) years from the grant date, at the discretion of and in the manner prescribed by the Nomination and Remuneration Committee of the Board.
	(d) Exercise price or pricing formula	The Exercise Price for Options will be ₹ 10/- per stock option. In any event, the Exercise price will not be below the face value of Equity Shares of the Company.

(e)	Maximum term of stock options granted	The Options granted shall vest equally over a period of 4 years subject to continued employment with the Company.
(f)	Source of shares (primary, secondary or combination)	Primary
(g)	Variation in terms of stock options	Not Applicable
(ii)	Method used to account for the Plan - Intrinsic or fair value	Fair value
(iii)	Where the company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the company shall also be disclosed.	The Company had opted for using the fair value method for expensing of the options. Hence, same is not be applicable.

Note: The Company has not granted any stock options during the Financial Year 2020-21 hence other disclosures as stipulated under SEBI Circular CIR/CFD/POLICY CELL/2/2015 dated June 16, 2015 is **not applicable**. The Options approved under the Plan are granted during FY 2021-22 and hence the complete disclosures as stipulated under SEBI Circular CIR/CFD/POLICY CELL/2/2015 dated June 16, 2015 will be provided in the next year's Annual Report.